NeuroMetrix — IPO Roadshow (January 2012)
24 slides from NeuroMetrix's IPO roadshow presentation, Jan 24, 2012
Slide 1: Better Patient Care Through Neurotechnology
CONFIDENTIAL Better Patient Care Through Neurotechnology CONFIDENTIAL Corporate Presentation Shai N. Gozani, MD, PhD, President & CEO Tom T. Higgins, CFO January 2012
Slide 2: Free Writing Prospectus Disclosure
CONFIDENTIAL CONFIDENTIAL Free Writing Prospectus Disclosure Issuer Free Writing Prospectus Filed Pursuant to SEC Rule 433 Dated January 24, 2012 Registration Statement No. 333-178165 On November 23, 2011, the issuer, NeuroMetrix, Inc., filed a Registration Statement on Form S-1 (Registration No. 33
Slide 3: Safe Harbor Statement
CONFIDENTIAL CONFIDENTIAL Safe Harbor Statement The statements contained in this corporate presentation include forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchang
Slide 4: NeuroMetrix, Inc. Focused on Diabetic Neuropathy
CONFIDENTIAL CONFIDENTIAL NeuroMetrix , Inc. Focused on Diabetic Neuropathy • Established medical device company • Proprietary medical devices that stimulate and measure nerves • Targeting $2B world - wide diabetic neuropathy market • NASDAQ listed under NURO Rapid growth in hospital discharges for
Slide 5: Strategy for Building Shareholder Value
CONFIDENTIAL CONFIDENTIAL Strategy for Building Shareholder Value Creating a Valuable Diabetes Franchise • Build diabetic neuropathy testing business • Develop and commercialize product pipeline • Expand and leverage multi - channel sales and distribution network • Consistent revenue growth
Slide 6: Shareholder Value Potential
CONFIDENTIAL CONFIDENTIAL Shareholder Value Potential • Typical physician purchases or prescribes about $2K annually • Company revenue directly tied to number of physician customers • Growing medical device companies may trade at 3 - 5 times revenue 0 40 80 120 160 0 5000 10000 15000 20000 $M Num. P
Slide 7: Diabetic Neuropathy: Common Complication of Diabetes
CONFIDENTIAL • Affects half of people with diabetes • Sensory loss, foot ulcers, amputation • Severe foot pain • Elevated cardiovascular risk • $14B annual direct cost in US Diabetic Neuropathy Common Complication of Diabetes National Diabetes Fact Sheet, 2011. Centers for Disease Control . Gordois
Slide 8: Diabetic Neuropathy is Progressive
CONFIDENTIAL Diabetic Neuropathy is Progressive Late Diagnoses Missed Treatment Opportunities Long Latent Period Severe Foot Pain Sensory Loss Foot Ulcer Perkins et al. Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic. Diabetes Care. 2001. Scollan - Koliopoulos et al. Percei
Slide 9: Diabetic Neuropathy Market: Large Opportunity, Unmet Needs
CONFIDENTIAL CONFIDENTIAL Diabetic Neuropathy Market Large Opportunity, Unmet Needs • $2B Market opportunity • Growing due to increasing diabetes prevalence • Unmet needs – Improved diagnostic methods – Better safety/efficacy of current products – Options targeting disease progression Health Advance
Slide 10: Extensive R&D Foundation
CONFIDENTIAL CONFIDENTIAL Extensive R&D Foundation 15 Years of Technology Development • Harvard Medical School and MIT spin - off • Proprietary nerve stimulation and detection technology – hardware, algorithms, consumables • Over 10 years of commercial use • Nearly 2M patients tested • Over 40 peer
Slide 11: Diabetes Product Pipeline
CONFIDENTIAL CONFIDENTIAL Diabetes Product Pipeline Assessment & Research Development Regulatory Commercial NC - stat® DPNCheck ™ point - of - care diabetic neuropathy test Q4 ‘11 SENSUS™ pain therapy Q2 ’12 510(k) Q4 ‘12 autonomic neuropathy testing Assess risk of heart attack and stroke external n
Slide 12: NC-stat DPNCheck
CONFIDENTIAL NC - stat DPNCheck Sophisticated proprietary technology • Accurate quantitative diagnostic test for diabetic neuropathy • Detects diabetic neuropathy before symptoms • One minute test • Straightforward interpretation • Hand - held device and single - patient use biosensor • Non - invasi
Slide 13: NC-stat DPNCheck
CONFIDENTIAL NC - stat DPNCheck Sophisticated proprietary technology • Accurate quantitative diagnostic test for diabetic neuropathy • Detects diabetic neuropathy before symptoms • One minute test • Straightforward interpretation • Hand - held device and single - patient use biosensor • Non - invasi
Slide 14: NC-stat DPNCheck Razor Razorblade Model
CONFIDENTIAL CONFIDENTIAL NC - stat DPNCheck Razor Razorblade Model • Biosensor ASP $15 - $20 • Gross margin 60 - 80% • Physician reimbursement is primarily patient pay • CPT code - 95905, limited insurance coverage • Typical charge $35 - 85 • Effort underway to expand coverage
Slide 15: SENSUS Pain Therapy Device
CONFIDENTIAL CONFIDENTIAL SENSUS™ Pain Therapy Device Painful Diabetic Neuropathy (PDN) • Pain relief (analgesia) in feet and lower legs • Non - invasive transcutaneous nerve stimulation effective in PDN • Wearable device and disposable electrode • Highly automated, easy - to - use • Used by patient
Slide 16: Hybrid Distribution Channel
CONFIDENTIAL CONFIDENTIAL Hybrid Distribution Channel Strategic and Cost Effective Endocrinologists 4000 Podiatrists 11,000 Primary Care 100,000 Managed Care Retail Medical Clinics and Pharmacies International distribution corporate corporate UK Office distribution direct • 10 sales representatives
Slide 17: Objectives and Milestones for 2012
CONFIDENTIAL CONFIDENTIAL Objectives and Milestones for 2012 Accelerate Commercialization, SENSUS Launch • Encouraging NC - stat DPNCheck Launch in 4Q ’11 • Key objectives – Quarter over quarter revenue growth – Develop managed care and retail medical market for NC - stat DPNCheck – Advance clinical
Slide 18: Resources to Implement Strategy in 2012
CONFIDENTIAL CONFIDENTIAL Resources to Implement Strategy in 2012 • $10M cash resources • Cash - flow positive legacy neurodiagnostic business • Debt free • New funding will support commercialization and pipeline
Slide 19: Management Team
CONFIDENTIAL CONFIDENTIAL Management Team Experienced, Tested, Tenured • 100 years in neuropathy technology and markets • Deep familiarity with diabetes • Long tenure with NeuroMetrix • Senior Management – Shai N. Gozani, MD, PhD Ph.D. President & CEO – Thomas T. Higgins Chief Financial Office
Slide 20: NeuroMetrix, Inc. Focused on Diabetic Neuropathy
CONFIDENTIAL CONFIDENTIAL NeuroMetrix , Inc. Focused on Diabetic Neuropathy • Established medical device company • Proprietary medical devices that stimulate and measure nerves • Targeting $2B world wide diabetic neuropathy market • Strategy for building shareholder value • Clear near term objective
Slide 21: Appendix
CONFIDENTIAL CONFIDENTIAL Appendix
Slide 22: Selected Financial Data
CONFIDENTIAL CONFIDENTIAL Selected Financial Data 2010 2009 Statement of Operations Data: Revenues $13,900 $26,137 Cost of revenues 7,050 7,536 Gross margin 6,850 18,601 Total operating expenses 24,160 25,570 Loss from operations (17,310) (6,969) Other 419 (4,948) Net loss ($16,891) ($11,917) 2010 2
Slide 23: Capitalization Schedule
CONFIDENTIAL CONFIDENTIAL Capitalization Schedule Notes: (1) Warrants to purchase common stock issued in connection with the September 2009 private placement exercisable at $13.20 per share. Upon a change in control (as defined) including a recapitalization, warrants will be exercised, redeemed by t
Slide 24: Shareholder Value Potential
CONFIDENTIAL CONFIDENTIAL Shareholder Value Potential $0 $10 $20 $30 $40 $50 $60 $70 1,000 4,000 7,000 10,000 13,000 16,000 19,000 22,000 25,000 REVENUE (Millions) Millions PHYSICIANS Installed Base Revenue Rev/Phy $1.5k Rev/Phy $2k Rev/Phy $2.5k $280 $240 $200 $160 $120 $80 $0 $40 VALUATION at 4X r